Your AI-Trained Oncology Knowledge Connection!
Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @SilasInman, LinkedIn, sinman@mjhlifesciences.com.
The combination of rituximab and lenalidomide followed by maintenance therapy with the same regimen did not improve response nor progression-free survival compared with rituximab and chemotherapy with rituximab maintenance for patients with previously untreated follicular lymphoma.
The FDA has approved a new breast-specific stereotactic body radiotherapy device known as GammaPod as a treatment for patients with breast cancer, based on findings from a 17-patient study.
Roche has announced plans to acquire the ROS1/TRK inhibitor entrectinib, through an all-cash $1.7 billion-dollar merger with Ignyta.
The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.
The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.
Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non
The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.
The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma.
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,
The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.
The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.
Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.
Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.
Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.
The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.
The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.
Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.
Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.
Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.
Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.
Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.
The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.
A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.
Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.
The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.
The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.
A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.
The FDA has approved letermovir to prevent cytomegalovirus infection and disease in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant.
